Calithera Biosciences, Inc. Announces Clinical Data Presentation At ASCO 2015
SOUTH SAN FRANCISCO, Calif., April 22, 2015 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced that clinical data for its lead drug candidate CB-839, the Company's novel, orally bioavailable glutaminase inhibitor, will be presented at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held from May 29 to June 2, 2015 in Chicago, Illinois. Clinical results to be presented include updated data from Calithera's Phase I trial in solid tumors. Calithera will hold an investor and analyst briefing Saturday, May 30, 2015 in Chicago, Illinois at 6:30 p.m. CT.
| Safety and tolerability of increasing doses of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase, in solid tumors | |
| Abstract: | #2512 |
| Presenter: | James J. Harding, MD, Memorial Sloan Kettering Cancer Center |
| Date: | May 30, 2015 |
| Poster Display: | 8:00 a.m. - 11:30 a.m. CT |
| Developmental Therapeutics and Translational Research, S Hall A, Board 228 | |
| Poster Discussion: | 1:15 p.m. - 2:30 p.m. CT, Room S406 |
About Calithera Biosciences
Calithera Biosciences is a clinical-stage company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology. Calithera's lead clinical candidate, CB-839, is a first-in-class inhibitor of glutaminase, a critical enzyme in tumor metabolism, and is currently being tested in patients with solid and hematological cancers. Calithera Biosciences is headquartered in South San Francisco. For more information about Calithera Biosciences, please visit www.calithera.com.
CONTACT: Jennifer McNealey ir@Calithera.com 650-870-1071
Help eployers find you! Check out all the jobs and post your resume.